Total No. of Questions: 3

Total No. of Printed Pages:2

Enrollment No.....



Faculty of Pharmacy End Sem Examination May-2024

PY3EL03 Pharmacovigilance

Programme: B. Pharm. Branch/Specialisation: Pharmacy

Duration: 3 Hrs. Maximum Marks: 75

Note: All questions are compulsory. Internal choices, if any, are indicated. Assume suitable data if necessary. Notations and symbols have their usual meaning.

		5 · · · · · · · · · · · · · · · · · · ·		
Q.1	i.	Enlist any two source of ADR reporting.	2	
	ii.	What is Nanjaro's scale?		
	iii.	Write any two responsibilities of CRO.	2	
	iv.	What is DDD?	2	
	v.	Define Pharmacogenomics.	2	
	vi.	Discuss Cohort study with example.	2	
	vii.	What is post approval phase?	2	
	viii.	Elaborate PSUR.	2	
	ix.	Write importance of Good clinical practices in	2	
		pharmacovigilance.		
	х.	Detail any two genetic related ADR.	2	
Q.2		Attempt any two:		
	i.	Define ADR. Explain the classification, detection of it with all the	10	
		methods used for the causality assessment in detail.		
	ii.	Elaborate about anatomical, therapeutic and chemical	10	
		classification of drugs.		
	iii.	(a) Discuss about PvPI with account on its importance in India. 5		
		(b) Write a detail note on MedDRA.	5	
Q.3		Attempt any seven: Two questions from each section is		
		compulsory.		
		Section - A		
	i.	Define vaccination. Explain the reasons for vaccination failure.	5	

P.T.O.

[2]

ii.	Describe the importance of communication in Drug safety crisis	
	management.	
iii.	Elaborate the targeted clinical investigation.	5
	Section - B	
iv.	Illustrate the organization and objectives of ICH.	5
v.	Write short note on PMS.	5
vi.	Give details on Drug therapy for pregnancy and lactation.	5
	Section - C	
vii.	Explain the Schedule Y of Drugs and Cosmetics Act in brief.	5
viii.	Describe in the detail about the organization structure & functions	5
	of CDSCO in India.	
ix.	Write a note on CIOMS working groups.	5

Marking Scheme

Pharmacovigilance (T) - PY3EL03 (T)

Q.1	i)	Two sources-	(As per ex	planation)	2	
	ii)	Defination -	(As per ex	planation)	2	
	iii)	Two responsibilities-	(As per ex	aplanation)	2	
	iv)	Defination	(As per ex	planation)	2	
	v)	Defination	(As per ex	planation)	2	
	vi)	Discission -	(As per ex	aplanation)	2	
	vii)	Defination -	(As per explanation)		2	
	viii)	Elaboration	(As per explanation)		2	
	ix)	Two importance	(As per explanation)		2	
	x)	Two genetic ADR	(As per ex	planation)	2	
Q.2	Atter	npt any two:				
	i.	Definition -	2 Ma	rks	10	
		classification -	4 Ma	rks		
		Detection -	2 Ma	rks		
		Causality assessment methods	2 Ma	rks		
	ii.	Elaboration of classification anatomica	l - 3 Ma	rks	10	
		Therapeutical -	4 Ma	rks		
		Chemical -	3 Ma	rks		
	iii.	Discussion	(As p	er explanation)	5	
		Note -	(As p	per explanation)	5	
Q.3	Atter	npt any seven: Two questions from each	section is	compulsory.		
		Section - A				
	i.	Defination -	2 Ma	rks	5	
		Reasons -	3 Ma	rks		
	ii.	Description -	5 Ma	rks	5	
	iii.	Elaboration -	(As p	per explanation)	5	
	Section - B					
	iv.	Organization -	2 Ma		5	
		Objectives -	3 Ma			
	v.	Note -	(As p	er explanation)	5	

P.T.O.

vi.	Details note -		(As per explanation)	5
		Section - C		
vii.	Explanation -		(As per explanation)	5
viii.	Description -		(As per explanation)	5
ix.	Details note -		(As per explanation)	5

[2]